Rapid Micro Biosystetms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

With offices in the US and Europe, Rapid Micro Biosystems has a singular focus on providing businesses a technology for automated rapid detection through the Growth Direct™ System.

The Growth Direct™ System, by Rapid Micro Biosystems, automates the detection and enumeration of colonies in microbial quality control in manufacturing.  The system includes 2 incubators, robotics and imaging systems that detect and enumerate microbial growth in about half the time of the traditional method.  By using the natural autoflouresence of living cells, the system “sees” colonies forming at about 100 cells, far sooner than the human eye. This allows the technology to provide results in about half the time of the traditional method while preserving the colony.

The Growth Direct™ System is designed to be a single test method for use with all the key tests in the microbial quality control lab including bioburden testing, environmental monitoring and sterility testing.  Sample preparation closely matches the existing tests, simplifying training of technicians. The technology can support all tests within one instrument, or each test within a separate unit.

Contact Details:

Company Name: Rapid Micro Biosystems
Address: One Oak Park Drive, Bedford, MA (USA)
Tel: +1 781 271 1444
Fax: +1 781 271 9905
Web: www.rapidmicrobio.com
Contact: Mark Severns
Email: sales@rapidmicrobio.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
FindPharma Custom Search

Click here